Venous valve, system and method

Information

  • Patent Grant
  • 11337812
  • Patent Number
    11,337,812
  • Date Filed
    Monday, November 27, 2017
    7 years ago
  • Date Issued
    Tuesday, May 24, 2022
    2 years ago
Abstract
A venous valve with a frame and a cover on the frame for unidirectional flow of a liquid through the valve.
Description
FIELD OF THE INVENTION

The present invention relates to apparatus, systems, and methods for use in a lumen; and more particularly to a valve apparatus, systems, and methods for use in the vasculature system.


BACKGROUND OF THE INVENTION

The venous system of the legs uses valves and muscles as part of the body's pumping mechanism to return blood to the heart. Venous valves create one way flow to prevent blood from flowing away from the heart. When valves fail, blood can pool in the lower legs resulting in swelling and ulcers of the leg. The absence of functioning venous valves can lead to chronic venous insufficiency.


Techniques for both repairing and replacing the valves exist, but are tedious and require invasive surgical procedures. Direct and indirect valvuoplasty procedures are used to repair damaged valves. Transposition and transplantation are used to replace an incompetent valve. Transposition involves moving a vein with an incompetent valve to a site with a competent valve. Transplantation replaces an incompetent valve with a harvested valve from another venous site. Prosthetic valves can be transplanted into the venous system, but current devices are not successful enough to see widespread usage.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate an embodiment of a valve according to the present invention.



FIG. 1C illustrates a cross-sectional view of the valve illustrated in FIG. 1A.



FIG. 1D illustrates a cross-sectional view of the valve illustrated in FIG. 1B.



FIGS. 1E and 1F illustrates an additional perspective view of the valve illustrated in FIG. 1A.



FIGS. 2A and 2B illustrate an embodiment of a valve in an expanded and collapsed state according to the present invention.



FIGS. 3A and 3B illustrate an embodiment of a valve according to the present invention.



FIG. 4A illustrates an embodiment of a valve according to the present invention.



FIG. 4B illustrates an embodiment of a valve according to the present invention.



FIG. 5A illustrates an embodiment of a valve according to the present invention.



FIG. 5B illustrates an embodiment of a frame for the valve illustrated in FIG. 5A according to the present invention.



FIG. 6 illustrates an embodiment of a system that includes a valve according to the present invention.



FIG. 7 illustrates an embodiment of a system that includes a valve according to the present invention.



FIG. 8 illustrates an embodiment of a system that includes a valve according to the present invention.



FIGS. 9A, 9B and 9C illustrate an embodiment of a system that includes a valve according to the present invention.



FIGS. 10A, 10B and 10C illustrate an embodiment of a system that includes a valve and a catheter having radiopaque markers according to the present invention.





DETAILED DESCRIPTION

Embodiments of the present invention are directed to an apparatus, system, and method for valve replacement or augmentation. For example, the apparatus can include a valve that can be used to replace or augment an incompetent valve in a body lumen. Embodiments of the valve can include a frame and cover that can be 30 implanted through minimally-invasive techniques into the body lumen. In one example, embodiments of the apparatus, system, and method for valve replacement or augmentation may help to maintain antegrade blood flow, while decreasing retrograde blood flow in a venous system of individuals having venous insufficiency, such as venous insufficiency in the legs.


The figures herein follow a numbering convention in which the first digit or digits correspond to the drawing figure number and the remaining digits identify an element or component in the drawing. Similar elements or components between different figures may be identified by the use of similar digits. For example, 110 may reference element “10” in FIG. 1, and a similar element maybe referenced as 210 in FIG. 2. As will be appreciated, elements shown in the various embodiments herein can be added, exchanged, and/or eliminated so as to provide a number of additional embodiments of valve. In addition, discussion of features and/or attributes for an element with respect to one Fig. can also apply to the element shown in one or more additional Figs. Embodiments illustrated in the figures are not necessarily to scale.



FIGS. 1A through 5B provide illustrations of various embodiments of a valve of the present invention. The valve can be implanted within the fluid passageway of a body lumen, such as for replacement or augmentation of a valve structure within the body lumen (e.g., a venous valve). In one embodiment, the valve of the present invention may be beneficial to regulate the flow of a bodily fluid through the body lumen in a single direction.



FIGS. 1A-1F illustrate one embodiment of a venous valve 100. Venous valve 100 includes a frame 102 and a cover 104 for the venous valve 100, where both the frame 102 and the cover 104 can resiliently radially collapse and expand, as will be described herein. Among other things, the frame 102 and the cover 104 define a lumen 106 of the valve 100. The lumen 106 allows for, amongst other things, fluid (e.g., blood) to move through the valve 100. The frame 102 also includes a first end 108 and a second end 110. The first end 108 and the second end 110 define a length of the frame 102 and of the valve 100. In one embodiment, the length of valve 100 can have a number of values. As will be appreciated, the length of valve 100 can be determined based upon the location into which the valve 100 is to be implanted. In other words, the length of the valve 100 can be patient specific. Examples of values for the length include, but are not limited to, 12 millimeters to 32 millimeters. Other values are also possible.


The frame 102 further includes an outer surface 112 and an inner surface 114 opposite the outer surface 112. In one embodiment, the cover 104 can be located over at least the outer surface 112 of the frame 102. For example, the cover 104 can extend around a perimeter of the frame 102 so as to completely cover the outer surface 112 of the frame 102. In other words, the cover 104 extends over the outer surface 112 of the frame 102 so that there are no exposed portions of the outer surface 112 of the frame 102. In an additional embodiment, the cover 104 can also be located over at least the inner surface 114 of the frame 102, as illustrated in FIGS. 1A-1F. A further embodiment includes the cover 104 located over at least a portion of the outer surface 112 and at least a portion of the inner surface 114.


The cover 104 can further include surfaces defining a reversibly sealable opening 116 for unidirectional flow of a liquid through the lumen 106. For example, the surfaces of the cover 104 can be deflectable between a closed configuration in which fluid flow through the lumen 106 can be restricted and an open configuration in which fluid flow through the lumen 106 can be permitted.


The frame 102 can be formed from a wide variety of materials and in a wide variety of configurations. Frame 102 can have a unitary structure with an open frame configuration. For example, the open frame configuration can include frame members 118 that define openings 120 across the frame 102 through which valve leaflets 122 formed by the cover 104 can radially-collapse and radially-expand, as will be described herein.


In addition, the first end 108 and the second end 110 each include a plurality of end portions 124 that lay on a common plane. The plurality of end portions 124, however, need not all lay on the common plane. In other words, it is possible that one or more of the end portions 124 of the frame 102 lay above and/or below the common plane.


While the frames illustrated herein, for example frame 102, are shown as having a circular configuration, other configurations are also possible. For example, the frame 102 could have an elliptical configuration. As such, the present invention should not be limited to the illustration of the frames, such as frame 102, provided herein.


As illustrated in FIGS. 1A-1F, the frame 102 can further include a first leaflet connection region 126 and a second leaflet connection region 128 adjacent the second end 110 of the frame 102. The first and second leaflet connection regions 126 and 128 further include an opening 130 through the frame 102. In the present example, the cover 104 can be coupled, as described more fully herein, to at least the first leaflet connection region 126 and the second leaflet connection region 128 using the openings 130 through the frame 102. The cover 104 so coupled can then move (e.g., pivot) relative the first leaflet connection region 126 and the second leaflet connection region 128 between an open valve configuration (illustrated in FIGS. 1A, 1C, and 1E) and a closed valve configuration (illustrated in FIGS. 1B, 1D, and 1F). As illustrated in the closed valve configuration, the open frame configuration of frame 102 allows cover 104 to move through the openings 120 in creating the reversible sealable opening 116 of the valve 100.


As illustrated in FIGS. 1A-1B and 1E-1F, the first leaflet connection region 126 and the second leaflet connection region 128 can be positioned opposite each other along a common axis. In addition, the first leaflet connection region 126 and the second leaflet connection region 128 can be radially symmetric around the longitudinal central axis 132 of the frame 102.


As illustrated, the first leaflet connection region 126 and the second leaflet connection region 128 can be positioned approximately one hundred eighty (180) degrees relative each other around the longitudinal central axis 132 of the frame 102. As will be appreciated, the first and second leaflet connection regions 126, 128 need not necessarily display an equally spaced symmetrical relationship as described above in order to practice the embodiments of the present invention. For example, the radial relationship can have the first and second leaflet connection region 126, 128 positioned at values greater than one hundred eighty (180) degrees and less than one hundred eighty (180) degrees relative each other around the longitudinal central axis 132 of the frame 102.


The frame member 118 of frame 102 can have similar and/or different cross-sectional geometries and/or cross-sectional dimensions along its length. The similarity and/or the differences in the cross-sectional geometries and/or cross-sectional dimensions can be based on one or more desired functions to be elicited from each portion of the frame 102. For example, the frame member 118 can have a similar cross-sectional geometry along its length. Examples of cross-sectional geometries include, but are not limited to, round (e.g., circular, oval, and/or elliptical), rectangular geometries having perpendicular sides, one or more convex sides, or one or more concave sides; semi-circular; triangular; tubular; I-shaped; T shaped; and trapezoidal.


Alternatively, the cross-sectional dimensions of one or more geometries of the frame member 118 can change from one portion of the frame 102 to another portion of the frame 102. For example, portions of the frame member 118 can taper (i.e., transition) from a first geometric dimension to a second geometric dimension different than the first geometric dimension. These embodiments, however, are not limited to the present examples as other cross-sectional geometries and dimension are also possible. As such, the present invention should not be limited to the frames provided in the illustration herein.


The valve 100 can further include a radial support member 134. The radial support member 134 can include a number of different configurations, as will be described herein. For example, as illustrated the radial support member 134 couples first leaflet connection region 126 and the second leaflet connection region 128. In addition to coupling the connection regions 126 and 128, the radial support member 134 can also serve to stabilize the relative positions of the connection regions 126 and 128 (e.g., limit relative fluctuations of the connection regions 126 and 128).


In the present embodiment, the radial support member 134 can be in the form of a tubular ring 136. The tubular ring 136 joins to the first leaflet connection region 126 and the second leaflet connection region 128. The tubular ring 136 can also move radially with the first and second leaflet connection region 124, 126 as the valve 100 radially collapses and expands.


In the various embodiments described herein, the tubular ring 136 can be configured to provide a spring force (e.g., elastic potential energy) to counter radial compression of the frame 102 towards its uncompressed state. For example, the tubular ring 136 can have a zig-zag configuration that includes corners 138 in from which a spring force (e.g., elastic potential energy) can be derived when the frame 102 is compressed. As will be appreciated, the corners 138 can have a number of configurations, including turns defining angles and/or arcs (e.g., having a radius of curvature). Additional spring force can be imparted to the frame 102 from the compression of the corners adjacent the first and second leaflet connection regions 126, 128 as well.


The valve 100 can further include a second tubular ring 140 located at the first end 108 of the frame 102. The second tubular ring 140 can have a similar, or 5 different, configuration as tubular ring 136 so as to impart the spring force to counter radial compression of the frame 102 towards its uncompressed state. In one embodiment, both the tubular ring 136 and the second tubular ring 140 help to stabilize the relative positions of the connection regions 126 and 128, as described herein, and to help maintain the position of the connection regions 126 and 128 relative the walls of a lumen in which the valve 100 has been implanted. As will be appreciated, the valve 100 could further include additional tubular rings located at one or more positions along the frame 102.


The compressible nature of the valve 100 can accommodate changes in body lumen size (e.g., diameter of the body lumen) by flexing to expand and/or contract to change the diameter of the frame 102. In one embodiment, the corner portions of the tubular rings 136 and 140, and the first leaflet connection region 126 and the second leaflet connection region 128 can act as springs to allow the valve 100 to resiliently radially collapse and expand. The frame 102 can also provide sufficient contact and expansion force with the surface of a body lumen wall to encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen around the edges of the frame 102 and the surface of a lumen when combined with a closed state of the valve leaflets attached thereto. Anchoring elements (e.g., barbs) can also be included with valve 100.



FIGS. 2A and 23 provide an example of the valve 200 in a collapsed state (FIG. 2A) and in an expanded state (FIG. 2B). As shown in FIGS. 2A and 2B, the valve 200 can travel between the collapsed and the expanded state along a radial travel path 240 (as shown in FIG. 2B), where there can be a change in a cross sectional area of lumen 206. For example, the frame 202 can travel along the radial travel path 242 so as to change a width of lumen 206. This can allow the valve 200 to react appropriately to the distension and contraction of a body lumen in which the valve 200 is placed.


Referring again to FIGS. 1A-1F, the corner portions of the tubular rings 136 and 140, and the first and second leaflet connection region 126 and 128 can also include, but are not limited to, other shapes that allow for repeatable travel between the collapsed state and the expanded state. For example, the elastic regions can include integrated springs having a circular or an elliptical loop configuration. The embodiments are not, however, limited to these configurations as other shapes are also possible.


The frame member 118 forming the tubular rings 136 and 140 can also include a radial flare 144. As illustrated, the radial flare 144 provides for an increase in the peripheral frame dimension at the first end 108 and/or the second end 110 of the frame 102. In one embodiment, the frame members 118 can be pre and/or post-treated to impart the radial flare 144. For example, frame members 118 forming the tubular rings 136 and 140 of the frame 102 could be bent to impart the radial flare 144. The frame 102 could then be heat treated so as to fix the radial flare 144 into the frame member 118. Other material treatments (e.g., plastic deformation, forging, elastic deformation with heat setting) are also possible to impart the radial flare as described herein, many of which are material specific.


The embodiments of the frame described herein can also be constructed of one or more of a number of materials and in a variety of configurations. The frame embodiments can have a unitary structure with an open frame configuration. The frame can also be self-expanding. Examples of self-expanding frames include those formed from temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range, such as Nitinol. Alternatively, the self-expanding frames can include those having a spring-bias. In addition, the frame 102 can have a configuration that allows the frame embodiments be radially expandable through the use of a balloon catheter.


The embodiments of the frame, such as frame 102 in FIGS. 1A-1F, can also be formed from one or more contiguous frame members. For example, the frame member 118 of frame embodiments can be a single contiguous member. The single contiguous member can be bent around an elongate tubular mandrel to form the frame. The free ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the frame. In an additional embodiment, the frame member 118 of frame 102 can be derived (e.g., laser cut, water cut) from a single tubular segment. In an alternative embodiment, methods of joining the frame member 118 to create the elastic region include, but are not limited to, welding, gluing, and fusing the frame member. The frame 102 can be heat set by a method as is typically known for the material which forms the frame 102.


The frame embodiments can be formed from a number of materials. For example, the frame can be formed from a biocompatible metal, metal alloy, polymeric material, or combination thereof. As described herein, the frame can be self-expanding or balloon expandable. In addition, the frame can be configured so as to have the ability to move radially between the collapsed state and the expanded state. Examples of suitable materials include, but are not limited to, medical grade stainless steel (e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof Additional frame embodiments may be formed from a shape-memory material, such as shape memory plastics, polymers, and thermoplastic materials. Shaped memory alloys having superelastic properties generally made from ratios of nickel and titanium, commonly known as Nitinol, are also possible materials. Other materials are also possible.


The lumen 106 can include a number of sizes. For example, the size of the lumen can be determined based upon the type of body lumen and the body lumen size in which the valve is to be placed. In an additional example, there can also be a minimum value for the width for the frame that ensures that the frame will have an appropriate expansion force against the inner wall of the body lumen in which the valve is being placed.


In one embodiment, the frame can further include one or more active anchoring elements. For example, the one or more active anchoring elements can include, but are not limited to, one or more barbs projecting from the frame 102.


The valve can further include one or more radiopaque markers (e.g., tabs, sleeves, welds). For example, one or more portions of the frame can be formed from a radiopaque material. Radiopaque markers can be attached to, electroplated, dipped and/or coated onto one or more locations along the frame. Examples of radiopaque material include, but are not limited to, gold, tantalum, and platinum.


The position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation (e.g., axial, directional, and/or clocking position) of the valve during its implantation. For example, radiopaque markers can be configured radially (e.g., around the radial support members 132 and 134) and longitudinally (e.g., on predetermined portions of longitudinally extending frame members 118) on predetermined portions of the frame 102 to allow the radial and axial position of the frame 102 to be determined. So in one embodiment a radiograph image of the frame 102 taken perpendicular to the valve leaflets 122 in a first clock position can produce a first predetermined radiograph image (e.g., an imaging having the appearance of an inverted “Y”) and a radiographic image taken perpendicular to the first and second leaflet connection regions 126, 128 in a second clock position can produce a second predetermined radiograph image (e.g., an imaging having the appearance of an upright “Y”) distinguishable from the first predetermined radiograph image.


In one embodiment, the first and second predetermined radiograph images allow the radial position of the leaflets 122 to be better identified within the vessel. This then allows a clocking position for the valve 100 to be determined so that the valve can be positioned in a more natural orientation relative the compressive forces the valve will experience in situ. In other words, determining the clocking of the valve as described herein allows the valve to be radially positioned in same orientation as native valve that it's replacing and/or augmenting.


As described herein, valve 100 further includes cover 104 having surfaces defining the reversibly sealable opening 116 for unidirectional flow of a liquid through the lumen 106. In one embodiment, the cover 104 extends over at least a portion of the frame 102 to the first and second leaflet connection regions 126, 128. The cover 104 extends between the first and second leaflet connection regions 126, 128 to provide a first valve leaflet 146 and a second valve leaflet 148 of the valve leaflets 122. The first and second valve leaflets 146, 148 include surfaces defining the reversibly sealable opening 116 extending between the first and second leaflet connection regions 126, 128 for unidirectional flow of a liquid through the valve 100.


In one embodiment, the material of the cover 104 can be sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets 122 for delivery by catheter to a location within a body lumen. The valve leaflets 122 can be constructed of a fluid-impermeable biocompatible material that can be either synthetic or biologic. Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polystyrene-polyisobutylene-polystyrene (SIBS), polyurethane, segmented poly(carbonate-urethane), Dacron, polyethlylene (PE), polyethylene terephthalate (PET), silk, Rayon, Silicone, or the like. Possible biologic materials include, but are not limited to, autologous, allogeneic or xenograft material. These include explanted veins and decellularized basement membrane materials (such as noncrosslinked bladder membrane or amnionic membrane), such as small intestine submucosa (SIS) or umbilical vein. As will be appreciated, blends or mixtures of two or more of the materials provided herein are possible. For example, SIBS can be blended with one or more basement membrane materials.


As described herein, a number of methods exist for attaching the cover 104 to the frame 102 so as to form the valve leaflets 122. For example, when positioned over the inter surface 114 of the frame 102, the cover 104 can be secured to the frame members 118 through the use of biocompatible staples, glues, sutures or combinations thereof. In an additional embodiment, the cover 104 can be coupled to the frame members 118 through the use of heat sealing, solvent bonding, adhesive bonding, or welding the cover 104 to either a portion of the cover 104 (i.e., itself) and/or the frame 102.


With respect to coupling the cover 104 to the first and second leaflet connection regions 126, 128, the cover 104 can be passed from the inner surface 114 and wrapped around at least a portion of the outer surface 112 adjacent the connection regions. For example, securing the cover 104 at the first and second leaflet connection regions 126, 128 can be accomplished by making longitudinal cuts of a predetermined length into the cover 104 adjacent the first and second leaflet connection regions 126, 128. In one embodiment, each cut creates two flaps adjacent each of the first and second leaflet connection regions 126, 128. The flaps can then pass through the frame adjacent the first and second leaflet connection regions 126, 128 and each of the two resulting flaps can be wrapped from the inner surface 114 around the frame 102 to the outer surface 112. The cover 104 can then be coupled to itself and/or the frame 102, as described herein. In addition, sutures can be passed through the opening 130 and the cover 104 so as to secure the cover 104 to the frame 102. In one embodiment, providing the flaps as described allows for the cover 104 to create a more fluid tight opening 116 in the area adjacent the first and second connection regions 126, 128.


As illustrated, the valve leaflets 122 include a region 150 of the cover 104 that can move relative the frame 102. The region 150 of the cover 104 can be unbound (i.e., unsupported) by the frame 102 and extends between the first and second leaflet connection regions 126, 128. This configuration permits the reversibly sealable opening 116 to open and close in response to the fluid pressure differential across the valve leaflets 122.


In an additional embodiment, the valve leaflets 122 in their open configuration have a circumference that is less than the circumference of the frame 102. For example, as illustrated, the valve leaflets 122 in their open configuration (FIG. 1A) include a transition region 152 where the circumference of the cover 104 changes from a first circumference to a second circumference that is smaller than the first circumference. In one embodiment, this better ensures that the valve leaflets 122 do not come into contact with the inner wall of the vessel in which the valve 100 is implanted.


In addition, the transition region 152 allows for a gap 154 between the outer surface of the valve leaflets 122 and the inner wall of the vessel in which the valve 100 is implanted. In one embodiment, the gap 154 can help prevent adhesion between the valve leaflets 122 and the vessel wall due to the presence of a volume of blood there between. The gap 154 can also allow for retrograde blood flow to be collected as the process of closing the valve leaflets 122 starts.


In one embodiment, the reversible sealable opening 116 also includes a lip 156. The lip 156 can have either a non-planar or a planar configuration. In one embodiment, whether the lip 156 has a planar or non-planar configuration can depend on what material is selected for forming the valve leaflets 122. For example, when a stiffer material (e.g., PTFE) is used for the valve leaflets 122 the lip 156 can have more of a concave shape than a planar or straight shape. In other words, as illustrated in FIGS. 1A and 1E, the lip 156 transitions from a first position adjacent the first and second leaflet connection regions 126, 128 to a second position lower than the first position as illustrated approximately midway between the first and second leaflet connection regions 126, 128. So, the lip 156 dips down to a low point approximately midway between the first and second leaflet connection regions 126, 128. In one embodiment, this shape allows the lip 156 to form a catenary when the valve leaflets 122 are in their closed position, as illustrated in FIG. 1F. In an alternative embodiment, when an elastic material is used for the valve leaflets 122 the lip 156 has more of a straight or planar shape. In other words, the lip 156 maintains essentially the same relative position around the circumference of the valve leaflets 122.


As will be appreciated, the lip 156 when the valve leaflets 122 are in their open configuration can have a non-round shape. For example, the lip 156 can have an eye shape or an oval shape with the major axis extending between the first and second leaflet connection regions 126, 128.


In one embodiment, under antegrade fluid flow (i.e., positive fluid pressure) from the first end 108 towards the second end 110 of the valve 100, the valve leaflets 122 can expand toward the inner surface 114 of the frame 102 to create an opening through which fluid is permitted to move. In one example, the valve leaflets 122 each expand to define a semi-tubular structure having an oval cross-section when fluid opens the reversibly sealable opening 116. An example of the open configuration for the valve is shown in FIGS. I A, 1 C and 1 E.


Under a retrograde fluid flow (i.e., negative fluid pressure) from the second end 110 towards the first end 108, the valve leaflets 122 can move away from the inner surface 114 as the valve leaflets 122 begin to close. In one example, the gap 20154 allows fluid from the retrograde flow to develop pressure on a first major face 158 of the valve leaflets 122. As fluid pressure develops, the valve leaflets 122 collapse, closing the reversibly sealable opening 116, thereby restricting retrograde fluid flow through the valve 100. An example of the closed configuration for the valve is shown in FIGS. IB, ID, and IF.


In an additional embodiment, the first major surface 158 of the valve leaflet 121 further include a concave pocket 160. For example, as illustrated in FIGS. IE and IF, the concave pocket 160 can be defined by a predefined portion of the cover 104 that moves relative the frame 102 as the valve opens and closes. In one embodiment, the concave pocket 160 includes specific dimensions relative a diameter of a vessel into which the valve 100 is to be implanted. For example, the concave pocket 160 can have a predetermined length-to-width ratio relative the diameter of the vessel in which the valve 100 is to be implanted. In one embodiment, the predetermined length-to-width ratio can be defined as:

H=(0.75)(D)

where H is the maximum height 162 of concave pocket 160, and D is a diameter 164 of the valve 100 taken between the first and second leaflet connection regions 126, 128.


Valve 100 provides an embodiment in which the surfaces defining the reversibly sealable opening 116 provide a hi-leaflet configuration (i.e., a bicuspid valve) for valve 100. Although the embodiments in FIGS. 1A-1F illustrate and describe a hi-leaflet configuration for the valve of the present invention, designs employing a different number of valve leaflets (e.g., tri-leaflet valve) maybe possible. For example, additional connection points (e.g., three or more) could be used to provide additional valve leaflets (e.g., a tri-leaflet valve).


The valve leaflets 122 can have a variety of sizes and shapes. For example, each of the valve leaflets 122 can have a similar size and shape. Alternatively, 15 each of the valve leaflets 122 need not have a similar size and shape (i.e., the valve leaflets can have a different size and shape with respect to each other).


In an additional embodiment, the valve leaflets 122 can include one or more support structures, where the support structures can be integrated into and/or onto the valve leaflets 122. For example, the valve leaflets 122 can include one or more support ribs having a predetermined shape. In one embodiment, the predetermined shape of the support ribs can include a curved bias so as to provide the valve leaflets 122 with a curved configuration. Support ribs can be constructed of a flexible material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when the valve leaflets 122 are urged into an open position, and stiff when the valve leaflets 122 are urged into a closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve. In an additional embodiment, support ribs can also be attached to frame 102 so as to impart a spring bias to the valve leaflets in either the open or the closed configuration.


As described herein, the cover 104 can be located over at least the inner surface 114 of the frame 102. FIGS. 1A and 1B illustrate an embodiment of this configuration, where the cover extending over the inner surface 114 also forms the valve leaflets 122 as described herein. Numerous techniques may be employed to laminate or bond cover 104 on the outer surface 112 and/or the inner surface 114 of the frame 102, including heat setting, adhesive welding, application of uniform force and other bonding techniques. Additionally, the cover 104 may be folded over the first end 108 of the frame 102 to provide the cover 104 on both the outer surface 112 and the inner surface 114. Cover 104 can also be joined to itself and/or the members 118 according to the methods described in U.S. Patent Application Publication US 2002/0178570 to Sogard et al., which is hereby incorporated by reference in its entirety.


The cover 104 can also be coupled to the connection regions so as to form the valve leaflets, as described herein. In one embodiment, the cover 104 can be in the form of a sheet or a sleeve of material, as described herein, which can be connected to the frame 102. Alternatively, the cover 104 can initially be in the form of a liquid that can be used to cast and/or form the cover over the frame 102. Other forms, including intermediate forms, of the cover 104 are also possible.


The cover 104 can be coupled to the frame 102, including the connection regions 126 and 128, in a variety of ways so as to provide the various embodiments of the valve of the present invention. For example, a variety of fasteners can be used to couple the cover 104 to the frame 102 so as to form the valve 100. Suitable fasteners can include, but are not limited to, biocompatible staples, glues, sutures or combinations thereof. In an additional embodiment, the cover 104 can be coupled to the frame 102 through the use of heat sealing, solvent bonding, adhesive bonding, or welding cover 104 to either a portion of the cover 104 (i.e., itself) and/or the frame 102.


The cover 104, including the valve leaflets 122, may also be treated and/or coated with any number of surface or material treatments. For example, the cover 104 can be treated with one or more biologically active compounds and/or materials that may promote and/or inhibit endothelization and/or smooth muscle cell growth of the cover 104, including the valve leaflets 122. Similarly, the cover 104 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from a either a donor or the host patient which are attached to the valve leaflets 122. The cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 122.


Cover 104, in addition to forming valve leaflets 122, can also be capable of inhibiting thrombus formation. Additionally, cover 104 may either prevent or facilitate tissue ingrowth there through, as the particular application for the valve 100 may dictate. For example, cover 104 on the outer surface 112 may be formed from a porous material to facilitate tissue ingrowth there through, while cover 104 on the inner surface 114 may be formed from a material or a treated material which inhibits tissue ingrowth.



FIGS. 3A and 3B illustrate an additional embodiment of the valve 300. Valve 300 includes frame 302 having an open frame configuration and the first and second leaflet connection regions 326, 328, as described herein. The leaflet connection regions 326 and 328 also provide a first vertex 361 and a second vertex 364, respectively, relative the first end 308 of the frame 302.


As illustrated, the outer surface 312 of the frame 302 can provide a number of frame dimensions. For example, the outer surface 312 of the frame 302 can be viewed as defining a first frame dimension 366 at the first end 308 of the frame 302 and a second frame dimension 368 between the first vertex 361 and the second vertex 364 of the frame 302. In one embodiment, the second frame dimension 368 can have a larger value as compared to the first frame dimension 366. Other dimensional relationships between the first and second frame dimensions 366 and 368 are also possible.


In the present embodiment, the differences in the frame dimensions for frame 302 allow portions of the frame members 318 to provide the radial support member tor the valve 300. In other words, the radial support member of the frame 302 20 can result from the relative shape and size of the different portions of the frame members 318. For example, as described herein the first and second frame dimensions 366, 368 can have different sizes, where the outer surface 312 of the frame 302 radially arcs from the first frame dimension 366 to the second frame dimension 368 so as to provide the radial support member of the frame 302.


So, in the present example the flaring of the of the frame member 318 from the first frame dimension 366 to the second frame dimension 368 allows the frame member 318 in the region of the first and second vertex 361 and 364 to provide the radial support member. In one embodiment, the frame members 318 can be pre and/or post treated to impart the frame dimension differences described herein. For example, frame members 318 forming the first vertex 361 and the second vertex 364 of the frame 302 could be bent to impart the radial flare. In one embodiment, a mandrel having a tapering surface could be used to impart the radial flare to the frame member 318.


The flared first and second vertex 361, 364 of the frame 302 could then be heat treated so as to fix the radial flare into the frame member 318. For example, a suitable heat treatment for a nitinol material can include heating the frame member 318 to approximately 500 degrees Celsius for approximately two (2) minutes. The frame members 318 can then be air cooled or quenched. Other material treatments (plastic deformation, forging, elastic deformation-heat setting) are also possible to impart the radial flare as described herein, many of which are material specific.


In one embodiment, the radial support member illustrated in FIG. 3 can serve to stabilize the valve 300 once positioned at a predetermined location as described 10 herein. In addition, the configuration of the radial support member can allow the first frame dimension 366 and the second frame dimension 368 to more closely correspond to each other once the valve 300 has been positioned at the predetermined location.


The valve 300 can thither include the cover 304, where both the frame 302 and the cover 304 can resiliently radially collapse and expand, as described herein. In the present example, the cover 304 can be located over at least the outer surface 312 of the frame 302 and coupled to the first and second leaflet connection regions 326 and 328 to form the valve leaflets 322 (e.g., the first and second valve leaflets 346 and 348) and the reversibly sealable opening 316, as described herein. In an additional embodiment, the cover 304 can also be located over at least the inner surface 314 of the frame 302. A further embodiment includes the cover 304 located over at least the outer surface 312 and the inner surface 314. Anchoring elements (e.g., barbs) and radiopaque markers can also be included with valve 300, as described herein.


As described herein, the valve leaflets 322 can include the transition region 352 where the circumference of the cover 304 changes from a first circumference to a second circumference that is smaller than the first circumference. The transition region 352 also allows for the gap 354, as described herein, to be formed between the outer surface of the valve leaflets 322 and the inner wall of the vessel in which the valve 300 is implanted. The valve leaflets 322 can also include the concave pocket 360, as described herein. Cover 304 also includes the lip 356 that can have either a non-planar or a planar configuration, as described herein.


Frame member 318 of the valve frame 302 can also include a variety of cross-sectional shapes and dimensions. For example, cross-sectional shapes for the frame member 318 can be as described herein. In addition, the frame member 318 can have two or more cross-sectional shapes, two or more different dimensions (e.g., a greater width and depth of the frame member 318 for the first and second vertices 361 and 364 as compared to the remainder of the frame member 318).



FIGS. 4A and 4B illustrate additional embodiments of the valve 400. As illustrated, the frame 402 includes an open frame configuration and the first leaflet connection region 426 and the second leaflet connection region 428, as described herein. FIGS. 4A and 4B illustrate embodiments in which the cover 404 can be positioned at different locations along the frame 402 so as to form the valve leaflets 422. For example, in FIG. 4A the leaflet connection regions 426 and 428 are located at the first vertex 461 and the second vertex 464, respectively, relative the first end 408 of the frame 402. In an additional example, FIG. 4B provides an illustration in which the leaflet connection regions 426 and 428 are positioned between the end of the frame 402 having the first vertex 461 and the second vertex 464 and the first end 408 of the frame 402.


The frame 402 can include multiple structural configurations. For example, the frame 402 can include a support frame region 470 that helps to stabilize and position the valve 400 inside a vessel. In one embodiment, FIGS. 4A and 4B provide an illustration in which the support frame region 470 extends from an axis 472 through a mid-point of the frame 402 away from the leaflet connection regions 426 and 428.


As illustrated, the outer surface 412 of the frame 402 can also provide a number of frame dimensions. For example, the outer surface 412 of the frame 402 can be viewed as defining the first frame dimension 466 at the axis 472 of the frame 402 and a second frame dimension 468 measure at either the first or second end 408, 410 of the frame 402. In one embodiment, the second frame dimension 468 can have a larger value as compared to the first frame dimension 466. Other dimensional relationships between the first and second frame dimensions 466 and 468 are also possible.


In the present embodiment, the differences in the frame 402 dimensions provide radial support members for the valve 400. In other words, radial support members of the frame 402 result from the relative shape and size of the different portions of the frame members 418. For example, as described herein the first and second frame dimensions 466, 468 can have different sizes, where the outer surface 412 of the frame 402 radially arcs from the first frame dimension 466 to the second frame dimension 468 so as to provide the radial support member of the frame 402. So, in the present example the flaring of the frame member 418 from the first frame dimension 466 to the second frame dimension 468 allows the frame member 418 in the region of the first and second vertex 461 and 464 to provide the radial support member.


In one embodiment, the radial support members illustrated in FIGS. 4A and 4B can serve to stabilize the valve 400 once positioned at a predetermined location as described herein. In addition, the configuration of the radial support member can allow the first frame dimension 466 and the second frame dimension 468 to more closely correspond to each other once the valve 400 has been positioned at the predetermined location.


The valve 400 can further include the cover 404, where both the frame 402 and the cover 404 can resiliently radially collapse and expand, as described herein. In the present example, the cover 404 can be located over at least the inner surface 414 of the frame 402 and coupled to the first and second leaflet connection regions 426 and 428 to form the valve leaflets 422 (e.g., the first and second valve leaflets 446 and 448) and the reversibly sealable opening 416, as described herein. In an additional embodiment, the cover 404 can also be located over at least the outer surface 412 of the frame 402. A further embodiment includes the cover 404 located over at least the outer surface 412 and the inner surface 414. Anchoring elements (e.g., barbs) and radiopaque markers can also be included with valve 400, as described herein.


Frame member 418 of the valve frame 402 can also include a variety of cross-sectional shapes and dimensions. For example, cross-sectional shapes for the frame member 418 can be as described herein. In addition, the frame member 418 can have two or more cross-sectional shapes, two or more different dimensions (e.g., a greater width and depth of the frame member 418 for one or more of the first and second vertices 461, 464 as compared to the remainder of the frame member 418).



FIGS. 5A and 5B illustrate an additional embodiment of the valve 500. Valve 500 includes the cover 504 as described herein. The frame 502 of the valve 500 further includes a triple wishbone configuration 574. In one embodiment, the triple wishbone configuration 574 of the frame 502 includes a series of interconnected bifurcated members having connection points that act as spring members, as will be described herein. In one embodiment, the interconnection of these members allows for the spring force of aligned springs integrated into the frame 502 to be added in series so as to increase the spring force potential of the frame 502.



FIG. 5B provides an illustration of the triple wishbone configuration 574 for the frame 502 that has been cut to provide it in a planar view. In one embodiment, the frame member 518 in the triple wishbone configuration 574 includes a radial support member 534. As illustrated, the radial support member 534 can be in the form of a tubular ring 536 that can move radially as the valve 500 radially collapses and expands.


In one embodiment, the tubular ring 536 can provide a spring force (e.g., elastic potential energy) to counter radial compression of the frame 502 towards its uncompressed state. For example, the tubular ring 536 has a zig-zag configuration that includes corners 538 that can develop the spring force when the frame 502 is under compressed. As will be appreciated, the corners 538 can have a number of configurations, including turns defining angles and/or arcs (e.g., having a radius of curvature).


The frame 502 further includes spring members 576 interconnected with the radial support member 534. As illustrated, the spring members 576 are associated with the radial support member 534 adjacent the corners 538. For example, the spring members 576 can include extensions 578 that join the radial support member 534 adjacent the corners 538 along a common plane 580. In the present embodiment, extensions 578 join the radial support member 534 adjacent each corner 538 along the plane 580.


The spring members 576 also include corners 538 that can develop the spring force when the frame 502 is under compressed. As will be appreciated, the corners 538 can have a number of configurations, including turns defining angles and/or 25 arcs (e.g., having a radius of curvature). In one embodiment, the corners 538 of the spring members 576 also provide the first and second leaflet connection regions 526, 528. In one embodiment, the spring members 576 interconnected with the radial support member 534 helps to stabilize the relative positions of the connection regions 526 and 528 (e.g., limit relative fluctuations of the connection regions 526 and 528).


The frame 502 can further include dimensional relationships, as described herein, which allow the frame 502 to flare radially outward relative the first end 508 of the frame. The valve 500 can further include the cover 504, where both the frame 502 and the cover 504 can resiliently radially collapse and expand, as described herein. In the present example, the cover 504 can be located over at least the inner surface 514 of the frame 502 and coupled to the first and second leaflet connection regions 526 and 528 to form the valve leaflets 522 (e.g., the first and second valve leaflets 546 and 548) and the reversibly sealable opening 516, as described herein.


The valve leaflets 522 can further include the transition region 552 where the circumference of the cover 504 changes from a first circumference to a second circumference that is smaller than the first circumference. The transition region 552 also allows for the gap, as described herein, to be formed between the outer surface of the valve leaflets 522 and the inner wall of the vessel in which the valve 500 is Implanted. The valve leaflets 522 can also include the concave pocket 560, as described herein. Cover 504 also includes the lip 556 that can have either a non-planar or a planar configuration, as described herein.


Frame member 518 of the valve frame 502 can also include a variety of cross-sectional shapes and dimensions. For example, cross-sectional shapes for the frame member 518 can be as described herein. In addition, the frame member 518 can have two or more cross-sectional shapes, two or more different dimensions (e.g., a greater width and depth of the frame member 518 for the corners 538 as compared to the remainder of the frame member 518).



FIG. 6 illustrates one embodiment of a system 680. System 680 includes valve 600, as described herein, reversibly joined to catheter 682. The catheter 682 includes an elongate body 684 having a proximal end 686 and a distal end 688, where valve 600 can be located between the proximal end 686 and distal end 688. The catheter 682 can further include a lumen 690 longitudinally extending to the distal end 688. In one embodiment, lumen 690 extends between proximal end 686 and distal end 688 of catheter 682. The catheter 682 can further include a guidewire lumen 692 that extends within the elongate body 684, where the guidewire lumen 692 can receive a guidewire for positioning the catheter 682 and the valve 600 within a body lumen (e.g., a vein of a patient).


The system 680 can further include a deployment shaft 694 positioned within lumen 690, and a sheath 696 positioned adjacent the distal end 688. In one embodiment, the valve 600 can be positioned at least partially within the sheath 696 and adjacent the deployment shaft 694. The deployment shaft 694 can be moved within the lumen 690 to deploy valve 600. For example, deployment shaft 694 can be used to push valve 600 from sheath 696 in deploying valve 600.



FIG. 7 illustrates an additional embodiment of the system 780. The catheter 782 includes elongate body 784, lumen 790, a retraction system 798 and a retractable sheath 796. The retractable sheath 796 can be positioned over at least a portion of the elongate body 784, where the retractable sheath 796 can move longitudinally along the elongate body 784. The valve 700 can be positioned at least partially within the retractable sheath 796, where the retractable sheath 796 moves along the elongate body 796 to deploy the valve 700.


In one embodiment, retraction system 798 includes one or more wires 701 coupled to the retractable sheath 796, where the wires are positioned at least partially within and extend through lumen 790 in the elongate body 784. Wires of the retraction system 798 can then be used to retract the retractable sheath 796 in deploying valve 700. In one embodiment, a portion of the elongate body 784 that defines the guidewire lumen 792 extends through the lumen 706 of the valve 700 to protect the valve 700 from the movement of the guidewire 709.



FIG. 8 illustrates an additional embodiment of the system 880. The catheter 882 includes elongate body 884, an inflatable balloon 803 positioned adjacent 20 the distal end 888. The elongate body 884 further includes an inflation lumen 805 longitudinally extending in the elongate body 884 of the catheter 882 from the inflatable balloon 803 to the proximal end 886. In one embodiment, an inflation pump 807 can be releasably coupled to the inflation lumen 805 and used to inflate and deflate the balloon 803.


In the present example, the inflatable balloon 803 can be at least partially positioned within the lumen 806 of the valve 800. The inflatable balloon 803 can be inflated through the lumen 805 with the inflation pump 807 to deploy the valve 800. The system 880 can further include the guidewire lumen 892 to receive a guidewire 809.



FIGS. 9A-9C illustrate an additional embodiment of the system 980. The system 980 includes a tubular sheath 911 having an elongate body 913 and a lumen 915. The system 980 further includes a delivery shaft 917 positioned within the lumen 915 of the tubular sheath 911. In one embodiment, the tubular sheath 911 and the delivery shaft 917 can move longitudinally relative each other.


System 980 also includes a flexible cover 919 between the tubular sheath 911 and the delivery shaft 917. In one embodiment, the flexible cover 919 is connected to the tubular sheath 911 and the delivery shaft 917 at a fluid tight seal 921 so as to prevent fluid from outside the system 980 entering the lumen 915. As illustrated, the valve 900 can be positioned over the delivery shaft 915 and the flexible cover 919 adjacent a distal end 923 of the delivery shaft 917.


In one embodiment, the tubular sheath 911, the delivery shaft 917 and the flexible cover 919 can each be formed from a number of different materials. For the tubular sheath examples include, but are not limited to materials selected from one or more of ePTFE, PTFE, PE, PET, silicone, and polyurethanes. For the delivery shaft 917 examples include, but are not limited to, those selected from a metal, a metal alloy, and/or a polymer. Examples include, but are not limited one or more of ePTFE, PTFE, PE, nylons, PET, silicone, polyurethanes, and stainless steel (e.g., 316L).


In addition, the delivery shaft 917 can also include a configuration that imparts sufficient column rigidity to allow it to be pushed and/or pulled through the lumen 915. For example, the delivery shaft 917 can be formed with reinforcing members bound within the body of the delivery shaft 917 (e.g., an elongate braid of stainless steel co-extruded with a polymer). For the flexible cover 919 examples include, but are not limited to, materials selected from one or more of cPTFE, PTFE, PE, PET, nylons, and polyurethanes. As will be appreciated, other materials and configurations for forming the tubular sheath 911, the delivery shaft 917 and the flexible cover 919 are also possible.


As illustrated in FIGS. 9A-9C, the valve 900 can be held in the same relative location 925 as it is being deployed. As illustrated in FIG. 9A, the valve 900, a portion of the flexible cover 919 and the delivery shaft 917 can be positioned within the lumen 915 of the tubular sheath 911. In one embodiment, the configuration illustrated in FIG. 9A allows the valve 900 to be delivered in its compressed state to a predetermined location in the lumen of the body. Once at the predetermined location, the sheath 911 can then be moved relative the delivery shaft 917. FIG. 9B illustrates a situation where the sheath 911 has been pulled over the valve 900 location 925 and at least partially over the delivery shaft 917.


As illustrated, the flexible cover 919 has a tubular configuration that folds back inside of itself (i.e., its lumen) as the tubular sheath 911 is drawn over the valve 900 and the delivery shaft 917. In one embodiment, the lumen 915 of the sheath 911 can contain a lubricating fluid (e. g., saline) to allow the flexible cover 919 to more easily pass over itself as illustrated. As the tubular sheath 911 continues to be pulled back relative the delivery shaft 917 until the valve 900 is released, as illustrated in FIG. 9C. In one embodiment, the valve 900 can include a self-expanding frame that allows the valve 900 to deploy at location 925 once released.


The embodiments of the present invention further include methods for forming the valve of the present invention, as described herein. For example, the method of forming the valve can include forming the frame having the leaflet connection regions, as described. The method can include providing the radial support member, or members, on the frame for the leaflet connection regions. As described herein, the radial support member can include the tubular rings and/or the radial flares imparted into the leaflet connection regions. The method also includes providing the cover on the frame, where connecting the cover to the leaflet connection regions provides at least the first leaflet and the second leaflet of the valve having surfaces defining the reversibly sealable opening for unidirectional flow of a liquid through the valve.


In an additional example, the valve can be reversibly joined to the catheter, which can include a process of altering the shape of the valve from a first shape, for example an expanded state, to the compressed state, as described herein. For example, the valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter. In one embodiment, positioning the valve at least partially within the sheath of the catheter includes positioning the valve in the compressed state adjacent the deployment shaft of the catheter. In an another embodiment, the sheath of the catheter functions as a retractable sheath, where the valve in the compressed state can be reversibly joined with the catheter by positioning the valve at least partially within the reversible sheath of the catheter. In a further embodiment, the catheter can include an inflatable balloon, where the balloon can be positioned at least partially within the lumen of the valve, for example, in its compressed state.


The embodiments of the valve described herein may be used to replace, supplement, or augment valve structures within one or more lumens of the body. For example, embodiments of the present invention may be used to replace an incompetent venous valve and help to decrease backflow of blood in the venous system of the legs.


In one embodiment, the method of replacing, supplementing, and/or augmenting a valve structure can include positioning at least part of the catheter including the valve at a predetermined location within the lumen of a body. For example, the predetermined location can include a position within a body lumen of a venous system of a patient, such as a vein of a leg.


In one embodiment, positioning the catheter that includes the valve within the body lumen of a venous system includes introducing the catheter into the venous system of the patient using minimally invasive percutaneous, transluminal catheter based delivery system, as is known in the art. For example, a guidewire can be positioned within a body lumen of a patient that includes the predetermined location. The catheter, including valve, as described herein, can be positioned over the guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location.


As described herein, the position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation (e.g., axial, directional, and/or clocking position) of the valve during its implantation. For example, radiopaque markers can be configured radially and longitudinally on predetermined portions of the valve frame and/or the elongate body of the catheter to indicate not only a longitudinal position, but also a radial position of the valve leaflets and the valve frame (referred to as a clock position). In one embodiment, the radiopaque markers are configures to provide radiographic images that indicate the relative radial position of the valve and valve leaflets on the catheter.



FIGS. 10A-10C provide an illustration of the radiopaque markers 1027 associated with the elongate body 1084 of the catheter 1082. As illustrated, the radiopaque markers 1027 include a radial component 1029 and a longitudinal component 1031. Depending upon the radial position of the catheter 1082, the radiopaque markers 1027 can provide a different and distinguishable radiographic image. For example, in a first position 1033 illustrated in FIG. 1OA the longitudinal component 1031 of the radiopaque markers 1027 are aligned so as to overlap. As the catheter 1082 is rotated, as illustrated in FIGS. 1OB and 1OC, the radiographic image of the radial component 1029 and/or longitudinal component 1031 of the radiopaque markers 1027 change.


The change in the relationship of the radial and longitudinal components 1029, 1031 as the catheter 1082 is rotated allows for the relative position of the valve, valve frame and valve leaflets to be determined from the radiographic image. For example, the relative position of the first and second leaflet connection regions 1026, 1028 could be aligned with longitudinal component 1031 other radiopaque markers 1027. This would allow the clock position for the valve 1000 to be determined so that the valve can be positioned in a more natural orientation relative the compressive forces the valve will experience in situ. In other words, the allowing for clocking of the valve 1000 as described herein allows the valve to be radially positioned in same orientation as native valve that it's replacing and/or augmenting.


As will be appreciated, other relative relationships between the radiopaque markers 1027 and the position of the valve 1000 on the catheter 1082 are possible. So, embodiments of the present invention should not be limited to the present example. For example, additional radiopaque markers 1027 on the valve I000 could be used either alone or in combination with radiopaque markers 1027 on the catheter 1082 to help in positioning the valve 1000 within a lumen.


The valve can be deployed from the catheter at the predetermined location in a number of ways, as described herein. In one embodiment, valve of the present invention can be deployed and placed in a number of vascular locations. For example, valve can be deployed and placed within a major vein of a patient's leg. In one embodiment, major veins include, but are not limited to, those of the peripheral venous system. Examples of veins in the peripheral venous system include, but are not limited to, the superficial veins such as the short saphenous vein and the greater saphenous vein, and the veins of the deep venous system, such as the popliteal vein and the femoral vein.


As described herein, the valve can be deployed from the catheter in a number of ways. For example, the catheter can include the retractable sheath in which valve can be at least partially housed, as described herein. Valve can be deployed by retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location. In an additional example, the catheter can include a deployment shaft and sheath in which valve can be at least partially housed adjacent the deployment shaft, as described herein. Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location. In an additional embodiment, the valve can be deployed through the use of an inflatable balloon.


Once implanted, the valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall. For example, the valve can be selected to have a larger expansion diameter than the diameter of the inner wall of the body lumen. This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve. As described herein, the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve. It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.


In addition, the use of both the radial support member and/or the support frame region of the valve can provide a self-centering aspect to valve within a body lumen. In one embodiment, the self-centering aspect resulting from the radial support member and/or the support frame region may allow valve to maintain a substantially coaxial alignment with the body lumen (e.g., such as a vein) as valve leaflets deflect between the open and closed configurations so as to better seal the reversible opening when valve is closed.


While the present invention has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the scope of the invention. As such, that which is set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined by the following claims, along with the full range of equivalents to which such claims are entitled.


In addition, one of ordinary skill in the art will appreciate upon reading and understanding this disclosure that other variations for the invention described herein can be included within the scope of the present invention. For example, the frame 102 and/or the cover 104 can be coated with a non-thrombogenic biocompatible material, as are known or will be known.


In the foregoing Detailed Description, various features are grouped together in several embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the embodiments of the invention require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.

Claims
  • 1. A prosthetic valve, comprising: an expandable stent having a scalloped inflow edge, a scalloped outflow edge, a first strut section, a second strut section, and an apex where two struts of the first strut section and two struts of the second strut section converge;wherein the first strut section and the second strut section are positioned longitudinally opposite each other along a longitudinal central axis of the expandable stent;wherein the expandable stent includes an opening extending radially through the expandable stent at the apex; anda cover comprising: a plurality of leaflets coupled to the expandable stent along at least a portion of the first strut section; anda sealing member disposed along an outer surface of the expandable stent.
  • 2. The prosthetic valve of claim 1, wherein the expandable stent includes a nickel-titanium alloy.
  • 3. The prosthetic valve of claim 1, wherein the expandable stent includes a cobalt alloy.
CROSS-REFERENCE TO RELATED U.S. APPLICATIONS

This application is a continuation of U.S. Ser. No. 14/678,430, filed Apr. 3, 2015, which is a continuation of U.S. Ser. No. 13/226,172, filed Sep. 6, 2011, which is a continuation of U.S. Ser. No. 11/150,331, filed Jun. 10, 2005, now U.S. Pat. No. 8,012,198, each of which is incorporated by reference, herein.

US Referenced Citations (640)
Number Name Date Kind
3671979 Moulopoulos Jun 1972 A
4291420 Reul Sep 1981 A
4787901 Baykut Nov 1988 A
4872874 Taheri Oct 1989 A
4935030 Alonso Jun 1990 A
4994077 Dobben Feb 1991 A
5002567 Bona et al. Mar 1991 A
5141491 Bowald Aug 1992 A
5163953 Vince Nov 1992 A
5219355 Parodi et al. Jun 1993 A
5254127 Wholey et al. Oct 1993 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5370685 Stevens Dec 1994 A
5411552 Andersen et al. May 1995 A
5469868 Reger Nov 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5643208 Parodi Jul 1997 A
5693087 Parodi Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5735859 Fischell et al. Apr 1998 A
5741326 Solovay Apr 1998 A
5741333 Frid Apr 1998 A
5800506 Perouse Sep 1998 A
5824061 Quijano et al. Oct 1998 A
5879320 Cazenave Mar 1999 A
5895419 Tweden et al. Apr 1999 A
5910170 Reimink et al. Jun 1999 A
6010531 Donlon et al. Jan 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6139575 Shu et al. Oct 2000 A
6287334 Moll et al. Sep 2001 B1
6312447 Grimes Nov 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6451054 Stevens Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461366 Seguin Oct 2002 B1
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6564805 Garrison et al. May 2003 B2
6569196 Vesely May 2003 B1
6602286 Strecker Aug 2003 B1
6629534 St.Goar et al. Oct 2003 B1
6635085 Caffey et al. Oct 2003 B1
6666885 Moe Dec 2003 B2
6666886 Tranquillo et al. Dec 2003 B1
6669725 Scott Dec 2003 B2
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6676702 Mathis Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6692512 Jang Feb 2004 B2
6695866 Kuehn et al. Feb 2004 B1
6695878 McGuckin, Jr. et al. Feb 2004 B2
6709456 Langberg et al. Mar 2004 B2
6709457 Otte et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B2
6716244 Klaco Apr 2004 B2
6719767 Kimblad Apr 2004 B1
6719784 Henderson Apr 2004 B2
6719786 Ryan et al. Apr 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6719790 Brendzel et al. Apr 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6723122 Yang et al. Apr 2004 B2
6723123 Kazatchkov et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6726716 Marquez Apr 2004 B2
6726717 Alfieri et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6730122 Pan et al. May 2004 B1
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6749630 McCarthy et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6752828 Thornton Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6761734 Suhr Jul 2004 B2
6761735 Eberhardt et al. Jul 2004 B2
6764494 Menz et al. Jul 2004 B2
6764508 Roehe et al. Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6770083 Seguin Aug 2004 B2
6780200 Jansen Aug 2004 B2
6786924 Ryan et al. Sep 2004 B2
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790231 Liddicoat et al. Sep 2004 B2
6793673 Kowalsky et al. Sep 2004 B2
6797000 Simpson et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6802860 Cosgrove et al. Oct 2004 B2
6805710 Bolling et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6810882 Langberg et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824562 Mathis et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B2
6840246 Downing Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6846324 Stobie Jan 2005 B2
6846325 Liddicoat Jan 2005 B2
6858039 McCarthy Feb 2005 B2
6869444 Gabbay Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875224 Grimes Apr 2005 B2
6875230 Morita et al. Apr 2005 B1
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6881224 Kruse et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6890352 Lentell May 2005 B1
6890353 Cohn et al. May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896700 Lu et al. May 2005 B2
6902576 Drasler et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6913608 Liddicoat et al. Jul 2005 B2
6916338 Speziali Jul 2005 B2
6918917 Nguyen et al. Jul 2005 B1
6921407 Nguyen et al. Jul 2005 B2
6921811 Zamora et al. Jul 2005 B2
6926715 Hauck et al. Aug 2005 B1
6926730 Nguyen et al. Aug 2005 B1
6929653 Strecter Aug 2005 B2
6932838 Schwartz et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939359 Tu et al. Sep 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6945957 Freyman Sep 2005 B2
6945978 Hyde Sep 2005 B1
6945996 Sedransk Sep 2005 B2
6945997 Huynh et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6951573 Dilling Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6955689 Ryan et al. Oct 2005 B2
6958076 Acosta et al. Oct 2005 B2
6962605 Cosgrove et al. Nov 2005 B2
6964682 Nguyen-Thien-Nhon et al. Nov 2005 B2
6964683 Kowalsky et al. Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6966925 Stobie Nov 2005 B2
6966926 Mathis Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976995 Mathis et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6986775 Morales et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6997950 Chawla Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7007396 Rudko et al. Mar 2006 B2
7011669 Kimblad Mar 2006 B2
7011681 Vesely Mar 2006 B2
7011682 Lashinski et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018407 Wright et al. Mar 2006 B1
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025780 Gabbay Apr 2006 B2
7033390 Johnson et al. Apr 2006 B2
7037333 Myers et al. May 2006 B2
7037334 Hlavka et al. May 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7044967 Solem et al. May 2006 B1
7048754 Martin et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7052487 Cohn et al. May 2006 B2
7052507 Wakuda et al. May 2006 B2
7063722 Marquez Jun 2006 B2
7066954 Ryan et al. Jun 2006 B2
7070616 Majercak et al. Jul 2006 B2
7070618 Streeter Jul 2006 B2
7077862 Vidlund et al. Jul 2006 B2
7081131 Thornton Jul 2006 B2
7087064 Hyde Aug 2006 B1
7089051 Jäverud et al. Aug 2006 B2
7090695 Solem et al. Aug 2006 B2
7267686 DiMatteo et al. Sep 2007 B2
7867274 Hill et al. Jan 2011 B2
8012198 Hill et al. Sep 2011 B2
8221492 Case et al. Jul 2012 B2
9028542 Hill et al. May 2015 B2
20010010017 Letac et al. Jul 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020026216 Grimes Feb 2002 A1
20020082630 Menz et al. Jun 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020138135 Duerig et al. Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020178570 Sogard et al. Dec 2002 A1
20020183835 Taylor et al. Dec 2002 A1
20020183838 Liddicoat et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030050694 Yang et al. Mar 2003 A1
20030055492 Shaolian et al. Mar 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030149477 Gabbay Aug 2003 A1
20030163194 Quijano et al. Aug 2003 A1
20030167071 Martin et al. Sep 2003 A1
20030171806 Mathis et al. Sep 2003 A1
20030199975 Gabbay Oct 2003 A1
20030209835 Chun Nov 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20030229395 Cox Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236569 Mathis et al. Dec 2003 A1
20040002719 Oz et al. Jan 2004 A1
20040003819 St.Goar et al. Jan 2004 A1
20040010305 Alferness et al. Jan 2004 A1
20040015230 Moll et al. Jan 2004 A1
20040015232 Shu et al. Jan 2004 A1
20040015233 Jansen Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040019377 Taylor et al. Jan 2004 A1
20040019378 Hlavka et al. Jan 2004 A1
20040024447 Haverich Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040030321 Fangrow, Jr. Feb 2004 A1
20040030381 Shu Feb 2004 A1
20040030382 St.Goar et al. Feb 2004 A1
20040030405 Carpentier et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040034408 Majercak et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040039442 St.Goar et al. Feb 2004 A1
20040039443 Solem et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044365 Bachman Mar 2004 A1
20040044403 Bischoff et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059351 Eigler et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040059412 Lytle, IV et al. Mar 2004 A1
20040060161 Leal et al. Apr 2004 A1
20040073301 Donlon et al. Apr 2004 A1
20040073302 Rourke et al. Apr 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040082923 Field Apr 2004 A1
20040082991 Nguyen et al. Apr 2004 A1
20040087975 Lucatero et al. May 2004 A1
20040088045 Cox May 2004 A1
20040088046 Speziali May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093080 Elmus et al. May 2004 A1
20040097979 Svanidze et al. May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102839 Cohn et al. May 2004 A1
20040102840 Solem et al. May 2004 A1
20040102842 Jansen May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040106991 Hopkins et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040122512 Navia et al. Jun 2004 A1
20040122513 Navia et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122515 Chu Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127980 Kowalsky et al. Jul 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133267 Lane Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040153052 Mathis Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040153147 Mathis Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040167539 Kuehn et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040176840 Langberg et al. Sep 2004 A1
20040181238 Zarbatany et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186561 McGuckin, Jr. et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193253 Thorpe et al. Sep 2004 A1
20040193260 Alferness et al. Sep 2004 A1
20040199155 Mollenauer Oct 2004 A1
20040199183 Oz et al. Oct 2004 A1
20040199191 Schwartz Oct 2004 A1
20040204758 Eberhardt et al. Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210303 Sedransk Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220654 Mathis et al. Nov 2004 A1
20040220657 Nieminen et al. Nov 2004 A1
20040225322 Samson et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Sase et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230297 Thornton Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040243153 Liddicoat et al. Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243228 Kowalsky et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260276 Rudko et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20040260389 Case Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050004583 Oz et al. Jan 2005 A1
20050004667 Swinford et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021056 St.Goar et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050027351 Reuter et al. Feb 2005 A1
20050027353 Alferness et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033419 Alferness et al. Feb 2005 A1
20050033446 Deem et al. Feb 2005 A1
20050038506 Nebler et al. Feb 2005 A1
20050038507 Alferness et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
20050049679 Taylor et al. Mar 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050049697 Sievers Mar 2005 A1
20050054977 Laird et al. Mar 2005 A1
20050055079 Duran Mar 2005 A1
20050055087 Starksen Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065460 Laird Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050065597 Lansac Mar 2005 A1
20050070998 Rourke et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075659 Realyvasquez et al. Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075723 Schroeder et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050075729 Nguyen et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080483 Solem et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050085903 Lau Apr 2005 A1
20050085904 Lemmon Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050096740 Langberg et al. May 2005 A1
20050101975 Nguyen et al. May 2005 A1
20050102026 Turner et al. May 2005 A1
20050107810 Morales et al. May 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119673 Gordon et al. Jun 2005 A1
20050119734 Spence et al. Jun 2005 A1
20050119735 Spence et al. Jun 2005 A1
20050125011 Spence et al. Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137449 Nieminen et al. Jun 2005 A1
20050137450 Aronson et al. Jun 2005 A1
20050137451 Gordon et al. Jun 2005 A1
20050137676 Richardson et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137685 Nieminen et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137700 Spence et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050143810 Dauner et al. Jun 2005 A1
20050143811 Realyvasquez Jun 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149179 Mathis et al. Jul 2005 A1
20050149180 Mathis et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050159810 Filsoufi Jul 2005 A1
20050159811 Lane Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165478 Song Jul 2005 A1
20050171472 Lutter Aug 2005 A1
20050171601 Cosgrove et al. Aug 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050184122 Hlavka et al. Aug 2005 A1
20050187614 Agnew Aug 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050187617 Navia Aug 2005 A1
20050192606 Paul, Jr. et al. Sep 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216039 Lederman Sep 2005 A1
20050216077 Mathis et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050222675 Sauter Oct 2005 A1
20050222678 Lashinski et al. Oct 2005 A1
20050228422 Machold et al. Oct 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050228486 Case et al. Oct 2005 A1
20050228494 Marquez Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228496 Mensah et al. Oct 2005 A1
20050234541 Hunt et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050240255 Schaeffer Oct 2005 A1
20050240259 Sisken et al. Oct 2005 A1
20050240262 White Oct 2005 A1
20050244460 Alferiev et al. Nov 2005 A1
20050246013 Gabbay Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050261704 Mathis Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267493 Schreck et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267565 Dave et al. Dec 2005 A1
20050267571 Spence et al. Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050267574 Cohn et al. Dec 2005 A1
20050272969 Alferness et al. Dec 2005 A1
20050273160 Lashinski et al. Dec 2005 A1
20050278015 Dave et al. Dec 2005 A1
20050283178 Flagle et al. Dec 2005 A1
20050288779 Shaoulian et al. Dec 2005 A1
20060000715 Whitcher et al. Jan 2006 A1
20060002075 Wei-Chieh et al. Jan 2006 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060009804 Pederson Jan 2006 A1
20060009841 McGuckin et al. Jan 2006 A1
20060009842 Huynh et al. Jan 2006 A1
20060013805 Hebbel et al. Jan 2006 A1
20060013855 Carpenter et al. Jan 2006 A1
20060015136 Besselink Jan 2006 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060020335 Kowalsky et al. Jan 2006 A1
20060020336 Liddicoat Jan 2006 A1
20060025750 Starksen et al. Feb 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025856 Ryan et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030747 Kantrowitz et al. Feb 2006 A1
20060030866 Schreck Feb 2006 A1
20060030882 Adams et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060036317 Vidlund et al. Feb 2006 A1
20060041305 Lauterjung Feb 2006 A1
20060041306 Vidlund et al. Feb 2006 A1
20060047297 Case Mar 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060047343 Oviatt et al. Mar 2006 A1
20060052804 Mialhe Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060064115 Allen et al. Mar 2006 A1
20060064116 Allen et al. Mar 2006 A1
20060064118 Kimblad Mar 2006 A1
20060064174 Zadno Mar 2006 A1
20060069400 Burnett et al. Mar 2006 A1
20060069429 Spence et al. Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060074483 Schrayer Apr 2006 A1
20060074484 Huber Apr 2006 A1
20060074485 Realyvasquez Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060089708 Osse et al. Apr 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060095125 Chinn et al. May 2006 A1
20060099326 Keogh et al. May 2006 A1
20060100697 Casanova May 2006 A1
20060100699 Vidlund et al. May 2006 A1
20060106278 Machold et al. May 2006 A1
20060106279 Machold et al. May 2006 A1
20060106456 Machold et al. May 2006 A9
20060111660 Wolf et al. May 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060111774 Samkov et al. May 2006 A1
20060116572 Case Jun 2006 A1
20060116756 Solem et al. Jun 2006 A1
20060122686 Gilad et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060127443 Helmus Jun 2006 A1
20060129235 Seguin et al. Jun 2006 A1
20060129236 McCarthy Jun 2006 A1
20060135476 Kutryk et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060135967 Realyvasquez Jun 2006 A1
20060136044 Osborne et al. Jun 2006 A1
20060136045 Flagle et al. Jun 2006 A1
20060136052 Vesely Jun 2006 A1
20060136054 Berg et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060142847 Shaknovich Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060142854 Alferness et al. Jun 2006 A1
20060149358 Zilla et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060149367 Sieracki Jul 2006 A1
20060149368 Spence Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060161250 Shaw Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060167542 Quintessenza Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20060190074 Hill et al. Aug 2006 A1
20110071625 Hill et al. Mar 2011 A1
Foreign Referenced Citations (169)
Number Date Country
0380666 Aug 1990 EP
0466518 Jan 1992 EP
2728457 Jun 1996 FR
1988000459 Jan 1988 WO
1990015582 Dec 1990 WO
1995001669 Jan 1995 WO
1996019159 Jun 1996 WO
1998003656 Jan 1998 WO
1998046115 Oct 1998 WO
1999004724 Feb 1999 WO
2000067679 Nov 2000 WO
2001015650 Mar 2001 WO
2001017462 Mar 2001 WO
2001028459 Apr 2001 WO
2001049213 Jul 2001 WO
2003047468 Jun 2003 WO
2003084443 Oct 2003 WO
2003094796 Nov 2003 WO
2004019825 Mar 2004 WO
2004021893 Mar 2004 WO
2004023980 Mar 2004 WO
2004030568 Apr 2004 WO
2004030569 Apr 2004 WO
2004030570 Apr 2004 WO
2004032724 Apr 2004 WO
2004032796 Apr 2004 WO
2004037128 May 2004 WO
2004037317 May 2004 WO
2004039432 May 2004 WO
2004043265 May 2004 WO
2004043273 May 2004 WO
2004043293 May 2004 WO
2004045370 Jun 2004 WO
2004045378 Jun 2004 WO
2004045463 Jun 2004 WO
2004047677 Jun 2004 WO
2004060217 Jul 2004 WO
2004060470 Jul 2004 WO
2004062725 Jul 2004 WO
2004066803 Aug 2004 WO
2004066826 Aug 2004 WO
2004069287 Aug 2004 WO
2004075789 Sep 2004 WO
2004080352 Sep 2004 WO
2004082523 Sep 2004 WO
2004082527 Sep 2004 WO
2004082528 Sep 2004 WO
2004082536 Sep 2004 WO
2004082537 Sep 2004 WO
2004082538 Sep 2004 WO
2004082757 Sep 2004 WO
2004084746 Oct 2004 WO
2004084770 Oct 2004 WO
2004089246 Oct 2004 WO
2004089250 Oct 2004 WO
2004089253 Oct 2004 WO
2004091449 Oct 2004 WO
2004091454 Oct 2004 WO
2004093638 Nov 2004 WO
2004093726 Nov 2004 WO
2004093728 Nov 2004 WO
2004093730 Nov 2004 WO
2004093745 Nov 2004 WO
2004093935 Nov 2004 WO
2004096100 Nov 2004 WO
2004103222 Dec 2004 WO
2004103223 Dec 2004 WO
2004105584 Dec 2004 WO
2004105651 Dec 2004 WO
2004112582 Dec 2004 WO
2004112585 Dec 2004 WO
2004112643 Dec 2004 WO
2004112652 Dec 2004 WO
2004112657 Dec 2004 WO
2004112658 Dec 2004 WO
2005000152 Jan 2005 WO
2005002424 Jan 2005 WO
2005002466 Jan 2005 WO
2005004753 Jan 2005 WO
2005007017 Jan 2005 WO
2005007018 Jan 2005 WO
2005007036 Jan 2005 WO
2005007037 Jan 2005 WO
2005009285 Feb 2005 WO
2005009286 Feb 2005 WO
2005009505 Feb 2005 WO
2005009506 Feb 2005 WO
2005011473 Feb 2005 WO
2005011534 Feb 2005 WO
2005011535 Feb 2005 WO
2005013860 Feb 2005 WO
2005018507 Mar 2005 WO
2005021063 Mar 2005 WO
2005023155 Mar 2005 WO
2005025644 Mar 2005 WO
2005027790 Mar 2005 WO
2005027797 Mar 2005 WO
2005034812 Apr 2005 WO
2005039428 May 2005 WO
2005039452 May 2005 WO
2005046488 May 2005 WO
2005046528 May 2005 WO
2005046529 May 2005 WO
2005046530 May 2005 WO
2005046531 May 2005 WO
2005048883 Jun 2005 WO
2005049103 Jun 2005 WO
2005055811 Jun 2005 WO
2005055883 Jun 2005 WO
2005058206 Jun 2005 WO
2005065585 Jul 2005 WO
2005065593 Jul 2005 WO
2005065594 Jul 2005 WO
2005070342 Aug 2005 WO
2005070343 Aug 2005 WO
2005072654 Aug 2005 WO
2005072655 Aug 2005 WO
2005079706 Sep 2005 WO
2005082288 Sep 2005 WO
2005082289 Sep 2005 WO
2005084595 Sep 2005 WO
2005087139 Sep 2005 WO
2005087140 Sep 2005 WO
2006000763 Jan 2006 WO
2006000776 Jan 2006 WO
2006002492 Jan 2006 WO
2006004679 Jan 2006 WO
2006005015 Jan 2006 WO
2006009690 Jan 2006 WO
2006012011 Feb 2006 WO
2006012013 Feb 2006 WO
2006012038 Feb 2006 WO
2006012322 Feb 2006 WO
2006019498 Feb 2006 WO
2006026371 Mar 2006 WO
2006026377 Mar 2006 WO
2006026912 Mar 2006 WO
2006027499 Mar 2006 WO
2006028821 Mar 2006 WO
2006029062 Mar 2006 WO
2006031436 Mar 2006 WO
2006031469 Mar 2006 WO
2006032051 Mar 2006 WO
2006034245 Mar 2006 WO
2006035415 Apr 2006 WO
2006041505 Apr 2006 WO
2006044679 Apr 2006 WO
2006048664 May 2006 WO
2006050459 May 2006 WO
2006050460 May 2006 WO
2006054107 May 2006 WO
2006054930 May 2006 WO
2006055982 May 2006 WO
2005051226 Jun 2006 WO
2006060546 Jun 2006 WO
2006063108 Jun 2006 WO
2006063181 Jun 2006 WO
2006063199 Jun 2006 WO
2006064490 Jun 2006 WO
2006065212 Jun 2006 WO
2006065930 Jun 2006 WO
2006066148 Jun 2006 WO
2006066150 Jun 2006 WO
2006069094 Jun 2006 WO
2006070372 Jul 2006 WO
2006073628 Jul 2006 WO
2006076890 Jul 2006 WO
2006011127 Feb 2007 WO
2006012068 Feb 2007 WO
Non-Patent Literature Citations (2)
Entry
EP Communication pursuant to Article 94(3) EPC regarding related EP Application No. 06772822.0-1526. dated Jun. 10, 2010, 4 pgs.
International Search Report dated Nov. 13, 2006 6 pgs.
Related Publications (1)
Number Date Country
20180078372 A1 Mar 2018 US
Continuations (3)
Number Date Country
Parent 14678430 Apr 2015 US
Child 15822747 US
Parent 13226172 Sep 2011 US
Child 14678430 US
Parent 11150331 Jun 2005 US
Child 13226172 US